|
1
|
Antonia SJ, Villegas A, Daniel D, Vicente
D, Murakami S, Hui R, Yokoi T, Chiappori A, Lee KH, de Wit M, et
al: Durvalumab after chemoradiotherapy in stage III non-small-cell
lung cancer. N Engl J Med. 377:1919–1929. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Paz-Ares L, Spira A, Raben D, Planchard D,
Cho BC, Özgüroğlu M, Daniel D, Villegas A, Vicente D, Hui R, et al:
Outcomes with durvalumab by tumour PD-L1 expression in
unresectable, stage III non-small-cell lung cancer in the PACIFIC
trial. Ann Oncol. 31:798–806. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Food and Drug Administration, . Durvalumab
prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/761069s029lbl.pdfJanuary
28–2022
|
|
4
|
Avrillon V, Daniel C, Boisselier P, Le
Péchoux C and Chouaid C: Nationwide real-life safety and treatment
exposure data on durvalumab after concurrent chemoradiotherapy in
unresectable stage III, locally advanced, non-small cell lung
cancer: Analysis of patients enrolled in the French early access
program. Lung. 200:95–105. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Faehling M, Schumann C, Christopoulos P,
Hoffknecht P, Alt J, Horn M, Eisenmann S, Schlenska-Lange A, Schütt
P, Steger F, et al: Durvalumab after definitive chemoradiotherapy
in locally advanced unresectable non-small cell lung cancer
(NSCLC): Real-world data on survival and safety from the German
expanded-access program (EAP). Lung Cancer. 150:114–122. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Jabbour SK, Lee KH, Frost N, Breder V,
Kowalski DM, Pollock T, Levchenko E, Reguart N, Martinez-Marti A,
Houghton B, et al: Pembrolizumab plus concurrent chemoradiation
therapy in patients with unresectable, locally advanced, stage III
non-small cell lung cancer: The phase 2 KEYNOTE-799 nonrandomized
trial. JAMA Oncol. 7:1–9. 2021.(Epub ahead of print). View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Durm GA, Jabbour SK, Althouse SK, Liu Z,
Sadiq AA, Zon RT, Jalal SI, Kloecker GH, Williamson MJ, Reckamp KL,
et al: A phase 2 trial of consolidation pembrolizumab following
concurrent chemoradiation for patients with unresectable stage III
non-small cell lung cancer: Hoosier cancer research network LUN
14–179. Cancer. 126:4353–4361. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Jabbour SK, Berman AT, Decker RH, Lin Y,
Feigenberg SJ, Gettinger SN, Aggarwal C, Langer CJ, Simone CB II,
Bradley JD, et al: Phase 1 trial of pembrolizumab administered
concurrently with chemoradiotherapy for locally advanced non-small
cell lung cancer: A nonrandomized controlled trial. JAMA Oncol.
6:848–855. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Garassino MC, Mazieres J, Reck M, Chouaid
C, Bischoff H, Reinmuth N, Cove-Smith L, Mansy T, Cortinovis D,
Migliorino MR, et al: Durvalumab after sequential chemoradiotherapy
in stage III, unresectable NSCLC: The phase 2 PACIFIC-6 trial. J
Thorac Oncol. 17:1415–1427. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Desilets A, Blanc-Durand F, Lau S,
Hakozaki T, Kitadai R, Malo J, Belkaid W, Richard C, Messaoudene M,
Cvetkovic L, et al: Durvalumab therapy following chemoradiation
compared with a historical cohort treated with chemoradiation alone
in patients with stage III non-small cell lung cancer: A real-world
multicentre study. Eur J Cancer. 142:83–91. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Liu Y, Yao L, Kalhor N, Carter BW, Altan
M, Blumenschein G, Byers LA, Fossella F, Gibbons DL, Kurie JM, et
al: Final efficacy outcomes of atezolizumab with chemoradiation for
unresectable NSCLC: The phase II DETERRED trial. Lung Cancer.
174:112–117. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Freels SA: Extracting summary statistics
to perform meta-analysis of the published literature for survival
endpoints. Stat Med. 23:18172004. View
Article : Google Scholar
|
|
13
|
Tierney JF, Stewart LA, Ghersi D, Burdett
S and Sydes MR: Practical methods for incorporating summary
time-to-event data into meta-analysis. Trials. 8:162007. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Guyot P, Ades AE, Ouwens MJNM and Welton
NJ: Enhanced secondary analysis of survival data: Reconstructing
the data from published Kaplan-Meier survival curves. BMC Med Res
Methodol. 12:92012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Offin M, Shaverdian N, Rimner A, Lobaugh
S, Shepherd AF, Simone CB II, Gelblum DY, Wu AJ, Lee N, Kris MG, et
al: Clinical outcomes, local-regional control and the role for
metastasis-directed therapies in stage III non-small cell lung
cancers treated with chemoradiation and durvalumab. Radiother
Oncol. 149:205–211. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
McCall NS, Janopaul-Naylor JR, McGinnis
HS, Kesarwala AH, Tian S, Stokes WA, Shelton JW, Steuer CE,
Carlisle JW, Leal TA, et al: Safety and efficacy of durvalumab
after concurrent chemoradiation in Black patients with locally
advanced non-small cell lung cancer. Cancer. 129:3713–3723. 2023.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Kartolo A, Shah H, Hopman W, As F,
Wheatley Price P and Robinson A: Consolidative durvalumab outcomes
in stage III non-small cell lung cancer in a multi-centre study.
Cancer Treat Res Commun. 29:1004962021. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Park CK, Oh HJ, Kim YC, Kim YH, Ahn SJ,
Jeong WG, Lee JY, Lee JC, Choi CM, Ji W, et al: Korean real-world
data on patients with unresectable stage III NSCLC treated with
durvalumab after chemoradiotherapy: PACIFIC-KR. J Thorac Oncol.
18:1042–1054. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Jazieh K, Gad M, Saad A, Wei W and Pennell
NA: Tumor PD-L1 expression is associated with outcomes in stage III
non-small cell lung cancer (NSCLC) patients treated with
consolidation durvalumab. Transl Lung Cancer Res. 10:3071–3078.
2021. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Landman Y, Jacobi O, Kurman N, Yariv O,
Peretz I, Rotem O, Dudnik E, Zer A and Allen AM: Durvalumab after
concurrent chemotherapy and high-dose radiotherapy for locally
advanced non-small cell lung cancer. Oncoimmunology.
10:19599792021. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Vrankar M, Stanic K, Jelercic S, Ciric E,
Vodusek AL and But-Hadzic J: Clinical outcomes in stage III
non-small cell lung cancer patients treated with durvalumab after
sequential or concurrent platinum-based chemoradiotherapy-single
institute experience. Radiol Oncol. 55:482–490. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Gennen K, Käsmann L, Taugner J, Eze C,
Karin M, Roengvoraphoj O, Neumann J, Tufman A, Orth M, Reu S, et
al: Prognostic value of PD-L1 expression on tumor cells combined
with CD8+ TIL density in patients with locally advanced non-small
cell lung cancer treated with concurrent chemoradiotherapy. Radiat
Oncol. 15:52020. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Denault MH, Feng J, Kuang S, Shokoohi A,
Leung B, Liu M, Berthelet E, Laskin J, Sun S, Zhang T, et al:
Beyond PACIFIC: Real-world outcomes of adjuvant durvalumab
according to treatment received and PD-L1 expression. Curr Oncol.
30:7499–7507. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Vrankar M, Zwitter M, Kern I and Stanic K:
PD-L1 expression can be regarded as prognostic factor for survival
of non-small cell lung cancer patients after chemoradiotherapy.
Neoplasma. 65:140–146. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Vrankar M, Kern I and Stanic K: Prognostic
value of PD-L1 expression in patients with unresectable stage III
non-small cell lung cancer treated with chemoradiotherapy. Radiat
Oncol. 15:2472020. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Tufman A, Neumann J, Manapov F, Sellmer L,
Jung A, Kauffmann-Guerrero D, Kahnert K, Mertsch P, Borgmeier A,
Semrau S, et al: Prognostic and predictive value of PD-L1
expression and tumour infiltrating lymphocytes (TiLs) in locally
advanced NSCLC treated with simultaneous radiochemotherapy in the
randomized, multicenter, phase III German intergroup lung trial
(GILT). Lung Cancer. 160:17–27. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Guberina M, Guberina N, Pöttgen C, Gauler
T, Richlitzki C, Metzenmacher M, Wiesweg M, Plönes T, Forsting M,
Wetter A, et al: Effectiveness of durvalumab consolidation in stage
III non-small-cell lung cancer: focus on treatment selection and
prognostic factors. Immunotherapy. 14:927–944. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Girard N, Bar J, Garrido P, Garassino MC,
McDonald F, Mornex F, Filippi AR, Smit HJM, Peters S, Field JK, et
al: Treatment characteristics and real-world progression-free
survival in patients with unresectable stage III NSCLC who received
durvalumab after chemoradiotherapy: Findings from the PACIFIC-R
study. J Thorac Oncol. 18:181–193. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Nindra U, Shahnam A, Stevens SX, Pal A,
Nagrial A, Lee J, Yip PY, Adam T, Boyer M, Kao S and Bray V:
Influence of EGFR mutation status and PD-L1 expression in stage III
unresectable non-small cell lung cancer treated with chemoradiation
and consolidation durvalumab. Asia Pac J Clin Oncol. 2023.(Early
Online). PubMed/NCBI
|
|
30
|
Raez LE, Arrieta O, Chamorro DF,
Soberanis-Piña PD, Corrales L, Martín C, Cuello M, Samtani S,
Recondo G, Mas L, et al: Durvalumab after chemoradiation for
unresectable stage III non-small cell lung cancer: Inferior
outcomes and lack of health equity in hispanic patients treated
with PACIFIC protocol (LA1-CLICaP). Front Oncol. 12:9048002022.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Kordbacheh T, Honeychurch J, Blackhall F,
Faivre-Finn C and Illidge T: Radiotherapy and anti-PD-1/PD-L1
combinations in lung cancer: Building better translational research
platforms. Ann Oncol. 29:301–310. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Wang Y, Kim TH, Fouladdel S, Zhang Z, Soni
P, Qin A, Zhao L, Azizi E, Lawrence TS, Ramnath N, et al: PD-L1
expression in circulating tumor cells increases during
radio(chemo)therapy and indicates poor prognosis in non-small cell
lung cancer. Sci Rep. 9:5662019. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Fujimoto D, Uehara K, Sato Y, Sakanoue I,
Ito M, Teraoka S, Nagata K, Nakagawa A, Kosaka Y, Otsuka K, et al:
Alteration of PD-L1 expression and its prognostic impact after
concurrent chemoradiation therapy in non-small cell lung cancer
patients. Sci Rep. 7:113732017. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Aredo JV, Mambetsariev I, Hellyer JA,
Amini A, Neal JW, Padda SK, McCoach CE, Riess JW, Cabebe EC, Naidoo
J, et al: Durvalumab for stage III EGFR-mutated NSCLC after
definitive chemoradiotherapy. J Thorac Oncol. 16:1030–1041. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Liu Y, Zhang Z, Rinsurongkawong W, Gay CM,
Le X, Ning MS, Lewis J, Rinsurongkawong V, Lee JJ, Roth J, et al:
Association of driver oncogene variations with outcomes in patients
with locally advanced non-small cell lung cancer treated with
chemoradiation and consolidative durvalumab. JAMA Netw Open.
5:e22155892022. View Article : Google Scholar : PubMed/NCBI
|
